These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 33421528)
1. Apoptotic regulator BCL-2 blockade as a potential therapy in classical Hodgkin Lymphoma. Gamboa-Cedeño AM; Díaz M; Cristaldo N; Otero V; Schutz N; Fantl D; Cugliari S; Zerga M; Rojas-Bilbao E; Jauk F; García Rivello H; Nuñez M; Ranuncolo SM Life Sci; 2021 Mar; 268():118979. PubMed ID: 33421528 [TBL] [Abstract][Full Text] [Related]
2. Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma. de Jong MRW; Langendonk M; Reitsma B; Nijland M; van den Berg A; Ammatuna E; Visser L; van Meerten T Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801186 [TBL] [Abstract][Full Text] [Related]
11. ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development. Cang S; Iragavarapu C; Savooji J; Song Y; Liu D J Hematol Oncol; 2015 Nov; 8():129. PubMed ID: 26589495 [TBL] [Abstract][Full Text] [Related]
12. Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies. Guièze R; Liu VM; Rosebrock D; Jourdain AA; Hernández-Sánchez M; Martinez Zurita A; Sun J; Ten Hacken E; Baranowski K; Thompson PA; Heo JM; Cartun Z; Aygün O; Iorgulescu JB; Zhang W; Notarangelo G; Livitz D; Li S; Davids MS; Biran A; Fernandes SM; Brown JR; Lako A; Ciantra ZB; Lawlor MA; Keskin DB; Udeshi ND; Wierda WG; Livak KJ; Letai AG; Neuberg D; Harper JW; Carr SA; Piccioni F; Ott CJ; Leshchiner I; Johannessen CM; Doench J; Mootha VK; Getz G; Wu CJ Cancer Cell; 2019 Oct; 36(4):369-384.e13. PubMed ID: 31543463 [TBL] [Abstract][Full Text] [Related]
13. Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma. Tam CS; Anderson MA; Pott C; Agarwal R; Handunnetti S; Hicks RJ; Burbury K; Turner G; Di Iulio J; Bressel M; Westerman D; Lade S; Dreyling M; Dawson SJ; Dawson MA; Seymour JF; Roberts AW N Engl J Med; 2018 Mar; 378(13):1211-1223. PubMed ID: 29590547 [TBL] [Abstract][Full Text] [Related]
14. Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal Prukova D; Andera L; Nahacka Z; Karolova J; Svaton M; Klanova M; Havranek O; Soukup J; Svobodova K; Zemanova Z; Tuskova D; Pokorna E; Helman K; Forsterova K; Pacheco-Blanco M; Vockova P; Berkova A; Fronkova E; Trneny M; Klener P Clin Cancer Res; 2019 Jul; 25(14):4455-4465. PubMed ID: 31004002 [TBL] [Abstract][Full Text] [Related]
15. The selective Bcl-2 inhibitor venetoclax, a BH3 mimetic, does not dysregulate intracellular Ca Vervloessem T; Ivanova H; Luyten T; Parys JB; Bultynck G Biochim Biophys Acta Mol Cell Res; 2017 Jun; 1864(6):968-976. PubMed ID: 27913204 [TBL] [Abstract][Full Text] [Related]
16. Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia. Del Poeta G; Postorino M; Pupo L; Del Principe MI; Dal Bo M; Bittolo T; Buccisano F; Mariotti B; Iannella E; Maurillo L; Venditti A; Gattei V; de Fabritiis P; Cantonetti M; Amadori S Drugs Today (Barc); 2016 Apr; 52(4):249-60. PubMed ID: 27252989 [TBL] [Abstract][Full Text] [Related]
17. Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia. Peirs S; Frismantas V; Matthijssens F; Van Loocke W; Pieters T; Vandamme N; Lintermans B; Dobay MP; Berx G; Poppe B; Goossens S; Bornhauser BC; Bourquin JP; Van Vlierberghe P Leukemia; 2017 Oct; 31(10):2037-2047. PubMed ID: 28074072 [TBL] [Abstract][Full Text] [Related]